

*Project Progress Summary*

<b>Title of the project:</b> European Community Respiratory Health Survey II		
<b>Acronym of the project:</b> ECRHS II		
<b>Type of contract:</b> Shared Cost		<b>Total project cost (in euro)</b> €2,400,000
<b>Contract number</b> QLK4-CT-1999-01237	<b>Duration (in months)</b> 48 Months	<b>EU contribution (in euro)</b> €2,400,000
<b>Commencement date</b> 01/03/00		<b>Period covered by the progress report</b> 01/03/01 – 28/02/02
<b><u>PROJECT COORDINATOR</u></b>		
<b>Name:</b> Peter Burney	<b>Title:</b> Professor	<b>Address:</b> Dept Public Health Sciences King's College London Capital House 42 Weston Street London SE1 3QD
<b>Telephone:</b> +44 20 7848 6610	<b>Fax:</b> +44 20 7848 6605	<b>E-mail address:</b> peter.burney@kcl.ac.uk
<b>Key words:</b>  asthma, allergy, environment		
<b>World wide web address (the project's www address )</b>  <u>www.ecrhs.org</u>		

**List of Participants (all partners are principal contractors; partner 1 is co-ordinator)**

<b>No</b>	<b>Organisation</b>	<b>Address</b>	<b>Principal Investigator</b>	<b>Tel</b>	<b>Fax</b>	<b>Email</b>
1	King's College London (KCOLL)	Dept Public Health Sciences, 42 Weston St, London SE1 3QD	P Burney	+44 207 848 6610	+44 207 848 6605	Peter.burney@kcl.ac.uk
2	University of Basel (UBAS)	Inst of Social and Preventive Medicine, Steinengraben 49, CH-4051 Basel	N Kuenzli	+41 61 267 6066	+41 61 267 6190	Nino.kuenzli@unibas.ch
3	GSF	Institute for Epidemiology, Inglostadter Landstrasse 1, D-85764 Neuherberg	J Heinrich	+49 89 318 74150	+49 89 318 73380	Joachim.heinrich@gsf.de
4	Hospital General de Albacete (UNS)	C/HNOS Falco S/N, E-02006 Albacete	J Martinez Moratalla Rovira	+34 967 597100	+34 96 724 39522	Jmmoratalla@terra.es
5	INSERM	Inserm U408, PO Box 416, Rue Henri Huchard, No 16, F-75870 Paris	F Neukirch	+33 142 291 541	+ 33 142 263 330	Neukirch@bichat.inserm.fr
6	CHUG	Service de Pneumologie, BP 217, F-38043 Grenoble	I Pin	+33 476 765 469	+33 476 765 830	Ipin@chu-grenoble.fr
7	Uppsala University (UUPP)	Dept Medical Sciences, Akademiska Sjukhuset, S-75185 Uppsala	C Janson	+461 8611 4115	+461 8611 2819	Christer.janson@medsci.uu.se
8	Goteborg University (UGOT)	Section of Occupational Medicine, St Sigfridsgatan 85B, S-41266 Goteborg	K Thoren	+463 133 54872	+463 140 9728	Kjell.toren@ymk.gu.se
9	Universita degli study di Verona (UVRN)	Dipartimento di Medicina e Sanita Pubblica, Strada Le Grazie 8, I-37134 Verona	R deMarco	+39 045 809 8629	+39 045 505357	Demarco@biometria.univr.it

10	Universita degli study di Pavia (UPAV)	Dipartimento do Scienze Sanitarie applicate, via Bassi 21, I-27100 Pavia	A Marinoni	+39 03 82 507534	+39 03 82 507570	Marinoni@unipv.it
11	IMIM	Carrer del Doctor aiguader 80, E-08003 Barcelona	J Anto	+34 93 2211009	+34-93 2213237	Jmanto@imim.es
12	Hospital de Galdakao (OSVS)	Servicio de Pneumologia, Barrio Labeage s/n, E-48960 Galakao	N Muniozguren	+34 94 400 7000	+34 94 457 1428	Jepidebi-san@ej-gv.se
14	Hospital Juan Ramon Jiminez (SASES)	Ronda Norte s/n, E-21005 Huelva	J Maldonado	+34 959 201 182	+34 959 204 450	Jmaldonado@terra.es
15	University of Groningen (RUGR)	Dept Epidemiology, Antonius Deusinglaan 1, NL-9713 AV	J Schouten	+31 50 363 2859	+31 50 363 3082	j.p.schouten@med.rug.nl
16	University of Antwerp (UIA)	Dept Respiratory Medicine, Universiteitlein 1, B-2610 Antwerp	P Vermeire	+32 820 2591	+32 820 2590	<a href="mailto:p.vermeir@uia.ua.ac.be">p.vermeir@uia, ua.ac.be</a>
17	Azienda Sanitaria Locale 4 Regione Piemonte (ASL4RP)	CPA_ASL4 Pneumologie, Lungo dora Savona 26, I-10152 Turin	M Bugiani	+39 11 240 3638	+39 11 240 3848	Mbugiani@qubisoft.it
18	University of Bergen (UIB)	Institute of Lung Medicine and Respiratory Physiology, University of Bergen, N-5021	A Gulsvik	+47 55 97 3242	+47 55 97 5149	Amund.gulsvik@meda.ui.b.no
19	Universtiy of Umea (UUME)	Dept of Respiratory Medicine and Allergy, Umea University Hospital, S-90185 Umea	E Norrman	+46 90 785 1863	+46 90 777 3817	Eva,norrman.us@vll.se
20	University Hospital of Iceland (NUHOSP)	Vifilstadir Chest Hospital, Vifilstadir, PO Box 210, Gardabaer	T Gislason	+35 4560 2800	+35 4560 2835	Thoraig@rsp.is
21	Tartu University (UTAR)	Faculty of Medicine, Veski 63, EE 2400	R Jogi	+37 27 449918	+37 27 449920	Rain.jogi@kliinikum.ee



**Objectives:**

1. To determine the incidence and prognosis of allergy, allergic disease and low lung function in adults living in Europe.
2. To describe the distribution of exposure to known or suspected environmental risk factors associated with the incidence and prognosis of allergy, allergic disease and low lung function.
3. To determine the risk attributable to chronic exposure to these environmental risk factors for the incidence and prognosis of allergy, allergic disease and low lung function.
4. To identify subgroups within the population based on gender, prior disease status, bronchial responsiveness and genetic risk who may be more susceptible to these environmental risk factors and measure their excess risk.
5. To establish a DNA bank taken from representative samples of the population that can be linked to health and environmental information.

**Results and Milestones:**

## WP1 (management of the project)

- database of all personnel in ECRHS and contacts maintained
- minutes of all meeting circulated. Two weekly 'Bulletin' of study progress e-mailed to all researchers engaged on project
- progress of partners and the central laboratory is monitored through regular reports
- regular appropriate communication with the Scientific Officer maintained
- queries from centres and ad hoc queries from other researchers and members of the public dealt with
- groups of researchers have formed working groups who meet at least once a year to discuss programmes of analysis
- steering committee have met once formally, once informally and twice via conference call to review progress and once with principal investigators and other research staff to report progress. Information and decisions made cascaded to principal investigators through minutes of meetings and Bulletin.

## WP2 (standardisation of assessment of participants at fieldwork centres)

- Quality Control visits to Pavia, Turin, Verona, Paris, Grenoble, Erfurt, Basle, Tartu, Umea, Goteburg and all Spanish centres were carried out
- Research paper describing protocol provisionally accepted by peer reviewed journal

## WP3 (collection of health data by all centres)

- 14 partners (16 centres) have finished health data collection
- 5 partners (6 centres) are collecting health data and one partner (2 centres) have yet to begin
- around 2680 participants (around 7820 in total) participants in total have been seen in a fieldwork centre

## WP4 (collection of analysis of dust)

- 8 partners (10 centres) have finished collecting dust samples through home visits
- 10 partners (11 centres) are collecting dust samples and one partner (2 centres) have yet to begin
- around 3200 participants (around 4000 in total) in total have provided dust samples



WP5 (Historical Air Pollution Data)

- A report for this workpackage is available (deliverable 4)
- A database of summary statistics has been established (deliverable 5)
- This workpackage is now complete

WP6 (PM<sub>2.5</sub> assessment at local Study centre)

- PM<sub>2.5</sub> monitoring has been completed for 18 partners (21 centres)
- An Air Pollution working group meeting was held in March 2001 and Sept 2001

WP7 (elemental analysis of filters)

- About 1600 filters have been analysed for elements using ED-RXF in the Swiss laboratory
- A report on methodology is available (deliverable 6)

WP8 (analysis of blood for specific and total IgE)

- About 2500 samples have been analysed

WP9 (establishment of DNA bank) *Not EU Funded*

- About 60 samples suitable for DNA extraction (around 3250 in total to date) have been collected
- 1960 samples have been transferred to the laboratory in Germany for storage and future extraction

WP 10 (assembly of data and creation of data files)

- 17 partners (20 centres) have sent data from short questionnaire

WP13 (association of occupation with health) *Partly EU Funded*

- An Occupational Working Group meeting was held in April 2001

WP14 (Working Group Quality of Life)

Data on quality of life has been collected from around 2680 participants (around 7820 in total)

WP15 (dissemination of study deliverables to policy makers and patient groups)

- Database of all ECRHS publications maintained
- All questionnaires are available at the co-ordinating centre
- Website of ECRHS II has been maintained and updated
- Leaflet detailing ECRHS II has been prepared and printed and 200 copies forwarded to the EC

---

**Benefits and Beneficiaries:**

The results will provide a database of internationally comparable information on changes in asthma, respiratory problems and allergy which will provide information as to how the global increase in the prevalence of asthma can be managed

---

**Future Actions:**

WP1 (management of project), WP6 (PM<sub>2.5</sub> assessment) and WP7 (elemental analyses on PM<sub>2.5</sub> filters)

- Will continue into the third reporting period





WP2 (standardisation of assessment), WP3 (collection of health data), WP4 (collection of dust samples), WP8 (analysis of blood for specific and total IgE)

- Will be completed during the next reporting period

WP9 (establishment of DNA bank)

- Samples will continue to be transferred to Partner 3 (GSF) during the next reporting period.
- Applications for extra funding for DNA extraction and analysis to be made

WP10 (assembly of data and creation of data files)

- Will continue during the third reporting period with all data being transferred to the co-ordinating centre

WP11 (analyses of association of air pollution with health) & WP12 (analysis of association of indoor pollutants with health)

- Will commence during the next reporting period.

WP13 (association of occupation with health) and WP14 (working group quality of life)

- Data collection will continue and analyses will commence when health data is available
- Working group meetings will be held

WP15 (dissemination of study)

- Website will be developed further
- Database of individuals who work in environment and health policy and of patient user groups organisations to be developed